They also found that the plasma Gal-3 median levels of de novo and relapsed non-M3 patients with AML were primarily higher than those of the non-M3 patients with AML during CR, which suggests that Gal-3 might be essential in the minimal residual disease (MRD) maintenance. This evidence concerns the gene LGALS3 and acute myeloid leukemia.